Methods for treating hepatitis C virus infectious disease

Patent metadata

Field	Value
Publication number	US-10195166-B2
Application number	US-201415032717-A
Country	US
Kind code	B2
Filing date	Oct 28, 2014
Priority date	Oct 29, 2013
Publication date	Feb 5, 2019
Grant date	Feb 5, 2019

Abstract

The present invention relates to a pharmaceutical composition for preventing or treating hepatitis C virus (HCV) infectious disease. More particularly, the present invention relates to a pharmaceutical composition for preventing or treating HCV infectious disease or an antiviral composition for HCV, containing at least one selected from the group consisting of: GRIM19 protein or a fragment thereof; and a gene encoding the protein or a fragment of the protein.

First claim

What is claimed is:

1. A method for treating a hepatitis C virus infectious disease, the method comprising:
selecting a subject in need of treatment for a hepatitis C virus infectious disease; and
administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising at least one selected from the group consisting of genes-associated with Retinoid-Interferon induced Morality 19 (GRIM19) protein or a fragment thereof, or a gene encoding the GRIM19 protein or the fragment thereof,
wherein the GRIM19 protein consists of the amino acid sequence of SEQ ID NO: 2,
wherein the gene encoding the GRIM19 protein consists of the base sequence of SEQ ID NO: 1, and
wherein the fragment of GRIM19 protein is at least one selected from the group consisting of:
a protein fragment comprising 1 st to 36 th amino acids of the amino acid sequence of SEQ ID NO: 2;
a protein fragment comprising 37 th to 72 nd amino acids of the amino acid sequence of SEQ ID NO: 2;
a protein fragment comprising 73 rd to 101 st amino acids of the amino acid sequence of SEQ ID NO: 2; and
a protein fragment comprising 102 nd to 144 th amino acids of the amino acid sequence of SEQ ID NO: 2.

2. The method of claim 1 , wherein the fragment of GRIM19 protein consists of the amino acid sequence selected from the group consisting of SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, and SEQ ID NO: 12.

3. The method of claim 1 , wherein the gene encoding the fragment of GRIM 19 protein is at least one selected from the group consisting of:
a gene comprising 3 rd to 108 th bases of the base sequence of SEQ ID NO: 1;
a gene comprising 109 th to 216 th bases of the base sequence of SEQ ID NO: 1;
a gene comprising 217 th to 303 rd bases of the base sequence of SEQ ID NO: 1; and
a gene comprising 304 th to 432 nd bases of the base sequence of SEQ ID NO: 1.

4. The method of claim 1 , wherein the gene encoding the fragment of GRIM19 protein consists of the base sequence selected from the group consisting of SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, and SEQ ID NO: 13.

5. The method of claim 1 , wherein the GRIM19 protein or the fragment thereof further comprises a cell penetrating peptide at an N-terminus, C-terminus, or both termini.

6. The method of claim 5 , wherein the cell penetrating peptide consists of the amino acid sequence selected from the group consisting of SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, and SEQ ID NO: 22.

7. The method of claim 1 , wherein the gene encoding the GRIM19protein or the fragment thereof is provided in a form included in a recombinant vector.

8. The method of claim 1 , wherein the composition further comprises a substance inhibiting expression or activity of diacylglycerol acyltransferase-1 (DGAT-1).

9. The method of claim 8 , wherein the substance inhibiting the expression or activity of DGAT-1 is siRNA, shRNA, or antisense oligonucleotide, specifically binding to the gene or mRNA of DGAT-1.

10. The method of claim 8 , wherein the substance inhibiting the expression or activity of DGAT-1 is an antibody, an aptamer, or a compound of Formula 1:

or a salt thereof, specifically binding to DGAT-1.

11. The method of claim 1 , wherein the composition further comprises a substance inhibiting expression or activity of RNA-dependent RNA polymerase.

12. The method of claim 11 , wherein the substance inhibiting the expression or activity of RNA-dependent RNA polymerase is a compound of Formula 2:

or a salt thereof.

13. The method of claim 1 , wherein the composition further comprises a substance activating AMP-activated protein kinase (AMPK).

14. The method of claim 13 , wherein the substance activating AMP-activated protein kinase (AMPK) is metformin.

15. The method of claim 1 , wherein the hepatitis C virus infectious disease is at least one of hepatitis C, liver fibrosis caused by hepatitis C virus, liver cirrhosis caused by hepatitis C virus, and liver cancer caused by hepatitis C virus.

Assignees

• Catholic Univ Korea Ind Academic Cooperation Foundation

Inventors

• Yoon Seung Kew
• Kim Jung Hee
• Hur Won Hee
• Cho Mi La
• Choi Jung Eun
• Lee Eun Byul

Classifications

• C12Y203/0102

  Diacylglycerol O-acyltransferase (2.3.1.20) · CPC title

• A61K31/155 Primary

  Amidines ([IMAGE cpc-sch-A61K-1029.gif]), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2) · CPC title

• A61P31/12

  Antivirals · CPC title

• A61P31/00

  Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics · CPC title

• C12N15/1137

  against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138) · CPC title